Search Results
Results found for "Roger Mills"
- 📰 GPCR Weekly News, October 23 to 29, 2023
Exscientia as EVP, Corporate Development Confo Therapeutics Nominated for 'Deal of the Year (>€500 Million
- 📰 GPCR Weekly News, October 2 to 8, 2023
Heptares and Verily Nominate First G-protein-coupled receptor Target for Therapeutic Development DKK 25 million
- 📰 GPCR Weekly News, September 25 to October 1, 2023
Receptor Agonist GSBR-1290 and Provides Program Update Septerna sells GPCR program to Vertex for $48 million
- 📰 GPCR Weekly News, September 18 to 24, 2023
Pfizer’s Vydura recommended by NICE for acute migraines Addex mGlu2 NAM Cognition Program Receives €4 Million
- 📰 GPCR Weekly News, September 11 to 17, 2023
Graeme Milligan and their colleagues research on Pro-phagocytic function and structural basis of GPR84 Biosciences' GPCR Assay Septerna: making another run on GPCRs Addex Mglu2 Nam Cognition Program Receives €4 Million
- 📰 GPCR Weekly News, August 21 to 27, 2023
nanobody binding to its extracellular domain Industry News Superluminal Medicines Launches with $33 Million
- 📰 GPCR Weekly News, July 31 to August 6, 2023
Oskar Industry News Addex GABAb Positive Allosteric Modulator Program To Receive Additional Chf 2.7 Million Half-Year 2023 Financial Results And Host Conference Call On August 10, 2023 X4 Pharmaceuticals Closes $115 Million Operational Highlights and Consolidated Results for the Second Quarter and First Half of 2023 Septerna: $150 Million
- 📰 GPCR Weekly News, July 10 to 16, 2023
Industry News Septerna Secures $150 Million in Series B Financing to Advance Pipeline of Novel GPCR-targeted
- 📰 GPCR Weekly News, May 15 to 21, 2023
Industry News X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market Andrew
- Artificial intelligence – faster, smarter, cheaper GPCR drug discovery
However, DL algorithms typically require large amounts of labelled training data comprising millions Unsupervised deep learning that takes advantage of large unlabelled data (e.g., millions of compounds
- 📰 GPCR Weekly News, April 17 to 23, 2023
Bryan Roth, Sudarshan Rajagopal, and Graeme Milligan. Save the date! Dr.
- VAMP2: a crucial player in the delivery of MOR to the synapse
Neurotransmitter release: The last millisecond in the life of a synaptic vesicle.
- 📰 GPCR Weekly News, April 3 to 9, 2023
Structural and Molecular Insights into GPCR Function Sub-millisecond conformational dynamics of the A2A
- 📰 GPCR Weekly News, March 27 to April 4, 2023
Publication of its Inaugural ESG Report, for the Financial Year ended 31 December 2022 Addex Raises $5.0 Million
- 📰 GPCR Weekly News - January 9 to 15, 2023
for Type II diabetes approved for first-line treatment The Lundbeck Foundation is awarding DKK 174 million
- 📰 GPCR Weekly News
Biosciences won Out-Licensing Deal of the Year from Locust Walk Omass Therapeutics 2022 Review Sosei hooks millions
- 📰 GPCR Weekly News
Therapeutics strengthens Scientific Advisory Board with appointment of immuno-oncology experts More millions
- Structure-Based Discovery of Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5
Chemical libraries containing fragment- (1.6 million molecules) and lead-like (4.6 million molecules)
- Structure-Based Discovery of Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5
Chemical libraries containing fragment- (1.6 million molecules) and lead-like (4.6 million molecules)
- Functional Characterization of the Venus Flytrap Domain of the Human TAS1R2 Sweet Taste Receptor
This study demonstrates the feasibility of producing milligram quantities of hTAS1R2-VFT to further characterize
- Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline ...
molecule candidates across oncology and immunology Exscientia will receive an upfront cash payment of $100 million
- Sosei Heptares Announces Antitrust Clearance of License Agreement with Neurocrine Biosciences
License Agreement Neurocrine Biosciences has agreed to pay Sosei Heptares an upfront payment of US$100 million
- Septerna emerges with $100M to spark 'second golden age' of prolific drug target GPCR with ...
decades—but the two-year-old biotech believes the area is still ripe for development, and it now has $100 million
- Structure Therapeutics Extends Financing, Advances Diabetes and Obesity Clinical Program and...
Structure Therapeutics), formerly known as ShouTi Inc., today announced it closed an oversubscribed $33 million financing round, extending its $100 million Series B financing, which was announced in October 2021.
- Anatomy of a partnership: Cancer Research UK teams up with Sosei Heptares
Cancer Research UK, a charity dedicated to funding lifesaving oncology research, spent £388 million on
- X4 slashes pipeline, lays off staff just three weeks after netting a $55M PIPE
The move comes less than three weeks after X4 pulled together a $55 million PIPE and amended a loan facility
- Third Rock pushes newest fund over $1B line as it marks 15 years in venture capital
2016, Abbie Celniker was promoted to partner at Third Rock Ventures as the firm raised just over $600 million
- Crinetics Pharmaceuticals Announces Pricing Of Underwritten Common Stock Offering
underwriting discounts and commissions and other offering expenses, are expected to be approximately $125.0 million

